Publications by authors named "Michael Bookman"

Claim this Profile
C
Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas.
Yvette Drew, Michael A Bookman

JAMA Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael A Bookman

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
Elizabeth Suh-Burgmann, Yun-Yi Hung, Holly Finertie, Haoyuan Zhong, Michael Bookman

Gynecol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
Quang D Ta, Connie Do, Kavita Sharma, Hormozan Zan Sorooshian, Merta Cushing, Michael Bookman

Gynecol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on inclusion, diversity, equity, and access in clinical trials: findings from a 6-continent survey.
Desislava Dimitrova, Jolijn Boer, Murat Karaman, Michael Bookman, Alison Brand

Int J Gynecol Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Jung-Min Lee, Mark F Brady, Austin Miller, Richard G Moore, Helen MacKay, Michael A Bookman

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Jubilee Brown, Austin Miller, Laura L Holman, Floor Backes, Christa Nagel, Michael A Bookman

Gynecol Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.
Jalid Sehouli, Jolijn Boer, Alison H Brand, Amit M Oza, Jennifer O'Donnell, Michael A Bookman

Int J Gynecol Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Carien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, Emma Allanson, Lauriane Eberst, Michael A Bookman

Lancet Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.
Paulette Mhawech-Fauceglia, Denis McCarthy, Akiko Tonooka, Giovanni Scambia, Yolanda Garcia, Michael Bookman

Gynecol Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker, Michael A Bookman

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Sandro Pignata, Michael Bookman, Jalid Sehouli, Austin Miller, Richard T Penson

Gynecol Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Aaron M Praiss, Austin Miller, Judith Smith, Stuart M Lichtman, Michael Bookman

Gynecol Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Tiffany Y Sia, William P Tew, Christopher Purdy, Dennis S Chi, Andrew W Menzin, Michael A Bookman

Gynecol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Charles N Landen, Luciana Molinero, Habib Hamidi, Jalid Sehouli, Austin Miller, Michael Bookman

Clin Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
Benoit You, Vasudha Sehgal, Balakrishna Hosmane, Xin Huang, Peter J Ansell, Michael A Bookman

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
Benoit You, Christopher Purdy, Larry J Copeland, Elizabeth M Swisher, Michael A Bookman

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Ignace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, Charlie Gourley, Mansoor Raza Mirza, Michael A Bookman

Lancet Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
Joyce F Liu, Mark F Brady, Ursula A Matulonis, Austin Miller, Elise C Kohn, Michael A Bookman

J Clin Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Junsik Park, Se Ik Kim, Soo Young Jeong, Yup Kim, Michael A Bookman

Gynecol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Elizabeth M Swisher, Carol Aghajanian, David M O'Malley, Gini F Fleming, Scott H Kaufmann, Michael A Bookman

Gynecol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Carol Aghajanian, Elizabeth M Swisher, Aikou Okamoto, Karina Dahl Steffensen, Michael A Bookman

Gynecol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Katherine C Fuh, Michael A Bookman, Joyce F Liu, Robert L Coleman, Thomas J Herzog

Gynecol Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Carol Aghajanian, Michael A Bookman, Gini F Fleming, Elizabeth M Swisher, Karina D Steffensen

Gynecol Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen N Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson

J Clin Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis